Drug profile · INN
retifanlimab
ZYNYZ
retifanlimab (ZYNYZ) is a programmed cell death protein 1 antagonist.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FF10
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — retifanlimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
retifanlimab (ZYNYZ) is a programmed cell death protein 1 antagonist.
Key facts
INN retifanlimab
Brand ZYNYZ
Mechanism Programmed cell death protein 1 antagonist
Target Programmed cell death protein 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FF10
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is retifanlimab?
retifanlimab (ZYNYZ) is a programmed cell death protein 1 antagonist.
What is the brand name for retifanlimab?
ZYNYZ is a marketed brand name for retifanlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.